ANV-419 is under clinical development by Anaveon and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ANV-419’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ANV-419 overview
ANV-419 is under development for the treatment of solid tumors including metastatic melanoma, renal cell carcinoma, non-small cell lung cancer, hepatocellular carcinoma, pancreatic cancer, colorectal cancer, esophageal cancer, adenoid cystic carcinoma. It is administered through intravenous route. The therapeutic candidate is a bi-specific fusion protein of an interleukin 2 (IL 2) receptor beta and gamma directed interleukin 2, linked to an anti-interleukin 2 antibody with high affinity to IL 2 receptor alpha binding domain of IL 2.
It was also under development for the treatment of kidney cancer, lung cancer, relapsed and refractory multiple myeloma.
Anaveon overview
Anaveon, a subsidiary of Syncona Ltd, is a clinical-stage company that develops cancer treatment drugs. Anaveon is headquartered in Basel, Basel-Landschaft, Switzerland.
For a complete picture of ANV-419’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
